About irinotecan hcl trihydrate
Anticancer topoisomerase I inhibitor
Used for
- Treats colorectal cancer, usually with other anticancer medicines.
- May be used alone or in combinations for other cancers, depending on treatment guidelines.
Usual adult dose
Varies by cancer and combination: commonly 180 mg/m² intravenously every two weeks with combination therapy, or 350 mg/m² every three weeks alone.
Common side effects
- Diarrhea, which can be severe
- Low blood counts and infection risk
- Nausea and vomiting
- Hair loss and fatigue
Important warnings
- Can cause life-threatening diarrhea and dehydration.
- May cause severe bone-marrow suppression and serious infections.
- Early diarrhea during infusion may occur with sweating, cramps, or runny nose.
- Dosing requires specialist monitoring and adjustment for toxicity or liver impairment.
Pregnancy
Can harm an unborn baby. Avoid during pregnancy; effective contraception is needed during treatment and for a period afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for one month after the last dose.
Interactions
- Strong CYP3A4 inhibitors or inducers can alter irinotecan exposure.
- Avoid St John’s wort; it can reduce irinotecan levels.
- Live vaccines may cause serious infection during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.